Skip to main content
Industry News
FDA clears Sorrento to launch COVID-19 antibody trial

The FDA granted Sorrento Therapeutics clearance to begin its early-stage trial to test its antibody candidate COVI-GUARD, or STI-1499, to treat patients hospitalized with COVID-19. The company is advancing the clinical program for STI-1499 for testing at sites in Brazil apart from the US program and plans to seek emergency use authorization.

Full Story: